MICHAEL A PACK
Medical Practice in Philadelphia, PA

6265157, Jul 24, 2001

Oct 3, 1997

8/943731

Darwin J. Prockop - Philadelphia PA
Loretta D. Spotila - Haddonfield NJ
Constantinos D. Deltas - Nicosia, CY
Larisa Sereda - Philadelphia PA
Andrea Westerhausen Larson - Forrest Hills PA
Michael Pack - Philadelphia PA
Alain Colige - Philadelphia PA
James Early - Upper Darby PA
Jarmo Korkko - Philadelphia PA
Leena Ala-Kokko - Oulu, FI
Susanna Annunen - Oulu, FI
Tero Pihlajamaa - Oulu, FI
Mirko Vuoristo - Oulu, FI
Petteri Paassilta - Oulu, FI

Allegheny University of the Health Sciences - Philadelphia PA
Thomas Jefferson University - Philadelphia PA
University of Oulu - Oulu

C12Q 168, C12P 1934, C07H 2104

435 6

Compositions and methods useful for determining whether a subject has an alteration in a gene encoding a protein chain of Type I or Type IX collagen are described. Novel intronic sequences of five human genes, COL1A1, COL1A2, COL9A1, COL9A2, and COL9A3 are described. Methods of determining the existence in a subject of a pathological condition associated with an altered gene encoding a Type I or Type IX collagen protein chain are provided, wherein such pathological conditions include diseases and disorders which are known to be associated with an altered gene encoding a Type I or Type IX collagen protein chain. Primers, probes, and methods of detecting a genetic predisposition of a subject for a pathological condition associated with an altered gene encoding a Type I or Type IX collagen protein chain are provided. Diseases and disorders for which the methods and compositions of the invention are useful for diagnostic or prognostic purposes include, but are not limited to osteoporosis, osteoarthritis, chondrodysplasia, multiple epiphyseal dysplasia, osteogenesis imperfecta, shortness of stature, scoliosis, low bone density, and degenerative joint disease.

2002016, Oct 31, 2002

Jan 30, 2002

10/062225

Steven Farber - Cherry Hill NJ, US
Michael Pack - Philadelphia PA, US

A01K067/027, C12Q001/68

800/003000, 800/020000

The present invention utilizes fluorescent lipids, particularly quenched phospholipid or cholesterol analogues, to facilitate screening for phenotypes representing perturbations of lipid processing; screening for genetic mutations that lead to disorders of phospholipid and/or cholesterol metabolism; and screening of compounds designed to treat disorders of phospholipid and/or cholesterol metabolism. The present invention is a mutant fish containing a metabolic defect affecting phospholipid and cholesterol processing. The mutant fish is useful for studying phospholipid and cholesterol metabolism and for screening compounds designed to treat disorders of phospholipid and/or cholesterol metabolism.

2011012, May 26, 2011

Dec 19, 2006

12/086948

Michael Pack - Philadelphia PA, US

A01K 67/00, C40B 30/06, C40B 40/02, A61K 31/55, C07D 487/04

800 8, 506 10, 506 14, 51421402, 540578

Provided is a method for high through-put screening for physiologic alterations in an altered teleost displaying a phenotype that is characteristic of the alteration and different from a wild-type, unaltered, matched teleost, comprising the steps of contacting the teleost displaying a genetically-inherited or chemically-induced phenotype with at least one test compound for a sufficient time and under suitable conditions to induce a response in the teleost indicative of pharmacological activity of the compound, and detecting and comparing the response with that of a matched, untreated, control, wherein a change in the teleost signal that is different from that of the control, indicates an altered phenotype and pharmacological activity of the at least one test compound. Further provided are the compounds identified by this method, the zebrafish having an altered phenotype resulting from treatment in accordance with these methods, and kits for facilitating the high through-put screening methods.

2002004, Apr 25, 2002

Oct 10, 2001

09/974550

Steven Farber - Cherry Hill NJ, US
Michael Pack - Philadelphia PA, US
Marnie Halpern - Pikesville MD, US

A01K067/027

800/003000, 800/020000

The present invention utilizes fluorescent lipids, particularly quenched phospholipid or cholesterol analogues, to facilitate screening for phenotypes representing perturbations of lipid processing; screening for genetic mutations that lead to disorders of phospholipid and/or cholesterol metabolism; and screening of compounds designed to treat disorders of phospholipid and/or cholesterol metabolism.

7488467, Feb 10, 2009

Jan 13, 2003

10/341538

Steven Farber - Cherry Hill NJ, US
Michael Pack - Philadelphia PA, US
Marnie Halpern - Pikesville MD, US

Trustees of the University of Pennsylvania - Philadelphia PA
Carnegie Institute of Washington - Washington DC

A61K 49/00

424 92, 424 111, 424 91

The present invention utilizes fluorescent lipids, particularly quenched phospholipid or cholesterol analogues, to facilitate screening for phenotypes representing perturbations of lipid processing; screening for genetic mutations that lead to disorders of phospholipid and/or cholesterol metabolism; and screening of compounds designed to treat disorders of phospholipid and/or cholesterol metabolism.

8124056, Feb 28, 2012

Jan 30, 2009

12/362698

Steven Farber - Baltimore MD, US
Michael Pack - Philadelphia PA, US
Marnie Halpern - Pikesville MD, US

Trustees of the University of Pennsylvania - Philadelphia PA
Carnegie Institution of Washington - Washington DC

A61K 49/00

424 92, 424 111, 424 165, 424 91

The present invention utilizes fluorescent lipids, particularly quenched phospholipid or cholesterol analogues, to facilitate screening for phenotypes representing perturbations of lipid and/or cholesterol processing in a vertebrate; screening for genetic mutations that lead to disorders of phospholipid and/or cholesterol metabolism; and screening of compounds designed to treat disorders of phospholipid and/or cholesterol metabolism in the vertebrate.